<?xml version='1.0' encoding='utf-8'?>
<document id="17394608"><sentence text="Anidulafungin--state of affairs from a clinical perspective." /><sentence text="Anidulafungin is the most recent development in the echinocandin class antifungals"><entity charOffset="0-13" id="DDI-PubMed.17394608.s2.e0" text="Anidulafungin" /><entity charOffset="52-64" id="DDI-PubMed.17394608.s2.e1" text="echinocandin" /><pair ddi="false" e1="DDI-PubMed.17394608.s2.e0" e2="DDI-PubMed.17394608.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17394608.s2.e0" e2="DDI-PubMed.17394608.s2.e1" /></sentence><sentence text=" Like other echinocandins, it inhibits 1,3-beta-d-glucan synthesis, thus achieving fungicidal activity against many Candida spp" /><sentence text=" including those resistant to fluconazole as well as fungistatic activity against some clinically important filamentous fungi, especially Aspergillus spp"><entity charOffset="30-41" id="DDI-PubMed.17394608.s4.e0" text="fluconazole" /></sentence><sentence text=" The drug is well tolerated, even in patients with renal or hepatic impairment" /><sentence text=" It has a low drug-drug interaction profile as it does not significantly interfere with the cytochrome P450 pathway" /><sentence text=" Anidulafungin has been approved for treatment of candidaemia, intra-abdominal abscesses, peritonitis and oesophageal candidiasis"><entity charOffset="1-14" id="DDI-PubMed.17394608.s7.e0" text="Anidulafungin" /></sentence><sentence text=" Trials have shown non-inferiority of anidulafungin to fluconazole in the treatment of invasive and non-invasive candidiasis"><entity charOffset="38-51" id="DDI-PubMed.17394608.s8.e0" text="anidulafungin" /><entity charOffset="55-66" id="DDI-PubMed.17394608.s8.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.17394608.s8.e0" e2="DDI-PubMed.17394608.s8.e0" /><pair ddi="false" e1="DDI-PubMed.17394608.s8.e0" e2="DDI-PubMed.17394608.s8.e1" /></sentence><sentence text=" After promising results from animal models, the role of anidulafungin in the treatment of invasive aspergillosis and other filamentous fungi is yet to be cleared"><entity charOffset="57-70" id="DDI-PubMed.17394608.s9.e0" text="anidulafungin" /></sentence><sentence text=" Currently, anidulafungin offers another alternative in the treatment of Candida infections, especially in patients where avoidance of drug-drug interactions is needed"><entity charOffset="12-25" id="DDI-PubMed.17394608.s10.e0" text="anidulafungin" /></sentence><sentence text=" Future investigations may elucidate how anidulafungin performs clinically in comparison with the other echinocandins"><entity charOffset="104-117" id="DDI-PubMed.17394608.s11.e0" text="echinocandins" /></sentence><sentence text="" /></document>